RDY Negative Sentiment Score: 40/100
Dr. Reddy's Laboratories Ltd. 8-2-337, Road No. 3, Banjara Hills Hyderabad - 500 034, Telangana, India CIN: L85195TG1984PLC004507 Tel: + 91 40 4900 2900 Fax: + 91 40 4900 2999 Email: mail@drreddys.com Web: www.drreddys.c
Saturday, September 6, 2025 1 min read
Key Takeaway: Dr. Reddy's Laboratories reported the completion of a GMP inspection by the USFDA at its API Mirfield facility in West Yorkshire, UK, which took place from September 1 to September 5, 2025. The inspection resulted in the issuance of a Form 483 detailing seven observations. The company is required to address these observations within a stipulated timeline. This development raises concerns regarding the compliance and operational integrity of the facility.
Full Press Release Details
National Stock Exchange of India Ltd. (Scrip Code: DRREDDY)
BSE Limited (Scrip Code: 500124)
New York Stock Exchange Inc. (Stock Code: RDY)
NSE IFSC Ltd. (Stock Code: DRREDDY)
This is to inform you that the United States Food & Drug Administration (USFDA) completed a GMP inspection at our API Mirfield facility in West Yorkshire, UK. The inspection was conducted from September 1 to September 5, 2025. We have been issued a Form 483 with 7 observations, which we will address within the stipulated timeline.
This is for your information and record.
For Dr. Reddy's Laboratories Limited
Company Secretary, Compliance Officer & Head-CSR